Obsidian Therapeutics (NASDAQ:OBX) Stock Rating Upgraded by Zacks Research

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by Zacks Research to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on OBX. Piper Sandler initiated coverage on shares of Obsidian Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $42.00 target price for the company. TD Cowen initiated coverage on shares of Obsidian Therapeutics in a research report on Thursday. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Obsidian Therapeutics Trading Down 3.0%

OBX opened at $27.50 on Thursday. Obsidian Therapeutics has a 1-year low of $23.00 and a 1-year high of $49.97.

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.